Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Do you know, that buy dildos is easy and safety?
Popular Articles

Another McGill/JGH Breakthrough Opens Door To Early Alzheimer's Diagnosis
A new diagnostic technique which may greatly simplify the detection of Alzheimer"s disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal"s Jewish General Hospital (JGH). Their results were published June 8 in the Journal of Alzheimer"s Disease. There is currently no accepted blood test for Alzheimer"s, and the diagnosis is usually based on expensive and labour-intensive neurological, neuropsychological and neuroimaging evaluations.
drugs without prescription
Treatable Hormonal Condition Sometimes Overlooked In Infertility Patients
A condition known as congenital adrenal hyperplasia, or CAH, is easily treatable but frequently overlooked or misdiagnosed, leading to infertility and other "perplexing symptoms," the New York Times reports. CAH is a hormone deficiency that leads to excess production of androgens, which can hinder ovulation in women and cause low sperm count in men. It also can cause short stature, body odor, acne, irregular menstruation and excessive hair growth. The condition can be diagnosed through a blood test and treated with small doses of the steroid dexamethasone, which can reverse symptoms in three months to two-and-one-half years.According to Maria New, a leading authority on CAH and a professor of pediatrics and human genetics at Mount Sinai School of Medicine, the disease occurs in one in every 100 people in the general population. It is more common among certain ethnic groups, occurring in one in 27 Ashkenazi Jews and one in 40 Hispanics. Not everyone with the condition has symptoms or needs to be treated. The most severe form of the disease, classic CAH, can result in ambiguous genitalia in girls, while the milder nonclassical form sometimes produce no symptoms, the Times reports.Many fertility clinics do not test for the disease or only test after attempting other treatments. Some obstetricians are unaware of CAH and its effect on fertility, according to Zev Rosenwaks, director of the Center for Reproductive Medicine at New York Presbyterian-Weill Cornell hospital. CAH also can be confused with polycystic ovarian syndrome -- which has some similar symptoms -- or early puberty in younger patients (Tarkan, New York Times, 7/7).
News of the day
Long-Term Care Proposal Draws Opposition
The insurance industry opposes a long-term care proposal called the CLASS Act, currently included in two major health care reform measures.
Sexual Health

$3.3 Million Awarded To University Of Liverpool, UK, For Genomics Hub

The University of Liverpool has been awarded ÷£2.2 million to establish a high-throughput genomic analysis hub for the North of England. The funding - comprising ÷£2 million from the Medical Research Council (MRC) and ÷£200,000 from the Northwest Regional Development Agency (NWDA) - is part of a ÷£7 million initiative by the MRC to boost the UK research community"s access to cutting-edge equipment for DNA sequencing with the establishment of high-throughput hubs in Scotland, the North of England and the East of England. The three hubs will receive funding for high-throughput sequencing machines which will be made available to all academics in the UK. Led by the University of Liverpool, the North of England hub will consolidate the expertise of four partner universities - Manchester, Sheffield, Lancaster and Liverpool - to accelerate the study of genetics in the UK and meet the challenges of research in tumour sequencing, genetic susceptibility and personalised medicine. It will be supported by the Clatterbridge Cancer Research Trust. The University already hosts the Advanced Genomics Facility which is a leading facility for pathogen sequencing, with client researchers from major companies and research institutions in the US, Germany, Sweden and Ireland. The hub will expand the capacity of this facility to make expertise and technology widely available to researchers and clinicians throughout the North of England. Professor Neil Hall, from the School of Biological Sciences and Principal Investigator of the North of England Hub, said: "There is a pressing need to understand the basis of genetic variation and to use it to define the most appropriate treatment for each patient with a particular condition. This "personalised medicine" will require establishing the DNA sequence of particular genes in those patients. Such research will benefit greatly from the new hub in the North of England by allowing much more productive sequencing technologies to be made available across the research community." John Jeans, MRC Chief Operating Officer, said: "This investment is key to retaining and enhancing the UK"s competitiveness. It makes plain the MRC"s commitment to supporting high quality basic research and exemplifies the responsiveness of MRC strategic investment to the needs of the research community." "Inviting regional applications has generated innovative partnerships between academic institutions, as well as engagement with industry, the NHS and Regional Genetics Services. This initiative will engender innovative ways of working and enable new and exciting discoveries. We hope the hubs will allow scientists to ask increasingly precise questions about diseases, and gather answers that were undreamt of only a decade ago." Kate Spark University of Liverpool


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009